Role of GRP78 in promoting therapeutic-resistant breast cancer

Katherine L. Cook, Robert Clarke

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations


Over 230,000 new cases of invasive breast cancer are diagnosed annually within the USA. Recurrent breast cancer remains a mostly incurable disease with drug resistance, tumor latency and distant metastases driving breast tumor recurrence and morbidity. Understanding drug resistance is a critical component of combating breast cancer. Recently, the protein chaperone GRP78 and the unfolded protein response were implicated as drivers of drug resistance. Preclinical studies show inhibiting GRP78 can reverse drug resistance. Furthermore, drugs developed to target GRP78 show clinical promise in several ongoing clinical trials.

Original languageEnglish (US)
Pages (from-to)1529-1534
Number of pages6
JournalFuture Medicinal Chemistry
Issue number12
StatePublished - Aug 1 2015
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 Future Science Ltd.


Dive into the research topics of 'Role of GRP78 in promoting therapeutic-resistant breast cancer'. Together they form a unique fingerprint.

Cite this